pipeline

microRNA biomarker discovery and development

TAmiRNA operates a fully equipped research and development laboratory for automated high-throughput screening of microRNA transcript levels in virtually any biological sample including cells, tissues and biofluids. TAmiRNA has further developed protocols for the isolation of microvesicles and RNA from various biofluids and tissues. A robust RNA profiling platform allows high throughput screening of full miRNome (~ 2000 microRNAs) down to specific sets of microRNAs. For this purpose TAmiRNA has implemented locked-nucleic-acid (LNA) based qPCR technologies as well as next-generation sequencing technologies. For testing the biological function of microRNAs, various molecular biology tools and in vitro bioassays have been developed in collaboration with the Grillari Labs and Evercyte. In collaboration with biostatisticians, bioinformaticians, and epidemiologists we achieve to identify and validate microRNA biomarkers with utility for diagnosis, prognosis, treatment monitoring and drug development.

biomarker development programs

TAmiRNA leverages the diagnostic potential of circulating microRNAs as surrogates of tissue health as well as important physiological processes for the development of novel diagnostic tests to improve the management of age-associated diseases.

As part of its most advanced development project, TAmiRNA has identified circulating microRNA biomarkers, which can be used to predict fracture risk in post-menopausal women and aged men – the osteomiR^® test. This novel biomarker is intended to facilitate early diagnosis and treatment of osteoporosis to prevent the risk of severe osteoporotic fractures.

The second advanced project in the pipeline is the thrombomiR^® test, a novel minimal-invasive surrogate parameter for platelet function. The thrombomiR^® test can be used to determine platelet activity retrospectively using stored plasma samples. Potential applications are the diagnosis of treatment response to anti-platelet therapy, identification of patients with high on-treatment platelet reactivity, and as readout to optimize drug dosage by balancing efficacy and bleeding risk In addition, the test could potentially be used as a predictive biomarker for the severity and adverse outcomes of cardiovascular disease.

Early stage projects of TAmiRNA in the area of liver disease, cancer and aging have recently been launched to ensure sustainable growth of TAmiRNA´s product pipeline in the future.

We are constantly looking to expand or product and technology pipeline through in-licensing of intellectual property from academia and industry.